catalyst calendar
CLIMB BIO INC · Data as of 2026-10-27
Late 2026
We expect to have initial B-cell and platelet data from the low dose cohort (250 mg at 24 weeks) in the Phase 1b/2a clinical trial in ITP in June 2026, with additional data from the higher dose cohort[s] anticipated by the end of 2026.Source filing
Late 2026
The Company expects to announce additional data from the study by year-end 2026.Source filing
1H 2027
Initial data from NAVIGATE-2 Phase 2 trial expected in 1H 2027Source filing
2027
Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027.Source filing
H1 2027
Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027Source filing
H1 2027
The NAVIGATE-2 Phase 2 trial is currently enrolling IgAN patients to confirm the Q12W dosing regimen, and a global Phase 3 trial is expected to initiate in 2027, pending regulatory feedback.Source filing
Q4 2026
Additional data from the ongoing Phase 1 study and initial reporting of Beijing Mabworks Biotech Co., Ltd. (Mabworks) Phase 1 healthy volunteer study in China to be presented at an upcoming medical meeting in the fourth quarter of 2026Source filing